VitaPath Genetics is a company.
VitaPath Genetics has raised $11.0M across 2 funding rounds.
Key people at VitaPath Genetics.
VitaPath Genetics has raised $11.0M in total across 2 funding rounds.
Key people at VitaPath Genetics.
VitaPath Genetics has raised $11.0M in total across 2 funding rounds.
VitaPath Genetics's investors include XSeed Capital.
VitaPath Genetics was a molecular diagnostics company that developed genomic-based tests to identify genetic variants affecting vitamin metabolism, enabling targeted therapies for preventable conditions like Spina Bifida via high-dose folic acid.[1][3] It served patients, physicians, and expectant mothers at risk for birth defects, solving the problem of undetected genetic mutations leading to serious diseases by providing actionable, CLIA-certified lab tests in a CAP-accredited facility.[1][3] The company raised $6 million in a 2009 Series A led by MDV-Mohr Davidow Ventures, with early seeding from X/Seed Capital, but ceased operations and is now listed as dissolved.[3][4]
Founded in 2009 in Foster City, California, VitaPath Genetics emerged from research at UC Berkeley's laboratory of Jasper Rine, focusing on the "Vitanome"—genomic information influencing vitamin metabolism.[1][3] Key inventors and leaders included Bruce Cohen (CEO), Dennis Gilbert, Nicholas Marini, and Jasper Rine, who developed assays for vitamin-remediable genetic variants.[1][3] Early traction came from validating a Spina Bifida test preventable by folic acid, securing seed funding from X/Seed Capital and the Series A, with board additions from investors Michael Goldberg (MDV) and Michael Borrus (X/Seed).[3] This positioned VitaPath to commercialize university-derived science for preventive medicine.[3]
VitaPath rode the early 2010s wave of personalized medicine and genomic diagnostics, aligning with trends in preventive healthcare amid rising genetic testing adoption post-Human Genome Project.[3] Timing was ideal as U.S. goals emphasized disease prevention to lower costs, with MDV's portfolio (e.g., Navigenics, CardioDx) amplifying its ecosystem role.[3] It influenced biotech by commercializing academic IP for vitamin genomics, paving the way for consumer-facing tests like 23andMe, though market forces like regulatory hurdles and competition limited scale.[1][3][4]
VitaPath's story highlights the promise—and pitfalls—of early genomics startups targeting niche preventive diagnostics, dissolving post-2009 funding amid biopharma consolidation.[4][6] No active pipeline, patents, or deals remain as of mid-2025 data.[4] Looking ahead, its Vitanome legacy could inspire revived efforts in nutrigenomics amid AI-driven genomics and precision health booms, potentially through acquirers or IP licensing. In a landscape favoring scalable platforms, VitaPath's specialized focus underscores the need for broader applications to endure, tying back to its core mission of turning genomic insights into everyday health prevention.[1][3]
VitaPath Genetics has raised $11.0M across 2 funding rounds. Most recently, it raised $5.0M Series C in August 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2012 | $5.0M Series C | XSeed Capital | |
| Nov 1, 2009 | $6.0M Series A | XSeed Capital |
